131 related articles for article (PubMed ID: 11777752)
1. Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab).
Stockis A; De Bruyn S; Deroubaix X; Jeanbaptiste B; Lebacq E; Nollevaux F; Poli G; Acerbi D
Eur J Pharm Biopharm; 2002 Jan; 53(1):49-56. PubMed ID: 11777752
[TBL] [Abstract][Full Text] [Related]
2. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations.
Vree TB; Dammers E; Valducci R
Int J Clin Pharmacol Ther; 2004 Aug; 42(8):463-72. PubMed ID: 15366327
[TBL] [Abstract][Full Text] [Related]
3. Influence of diet on the single-dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate.
Sata H; Inoue K; Nii T; Kuroda T
Biol Pharm Bull; 1997 Oct; 20(10):1111-5. PubMed ID: 9353575
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation.
Kosoglou T; Patrick JE; Cohen A; Radwanski E; Christopher D; Affrime MB
Clin Ther; 1995; 17(2):241-51. PubMed ID: 7614524
[TBL] [Abstract][Full Text] [Related]
5. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
Tam SW; Sabolinski ML; Worcel M; Packer M; Cohn JN
Clin Pharmacokinet; 2007; 46(10):885-95. PubMed ID: 17854237
[TBL] [Abstract][Full Text] [Related]
6. Relative bioavailability of two isosorbide dinitrate sublingual tablet formulations administered as single doses in healthy subjects.
Niopas I; Daftsios AC; Nikolaidis N
Int J Clin Pharmacol Ther; 2001 May; 39(5):224-8. PubMed ID: 11380069
[TBL] [Abstract][Full Text] [Related]
7. Single and multiple dose pharmacokinetic studies of oral sustained release and non-sustained release formulations of isosorbide-5-mononitrate in healthy volunteers.
Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
Arzneimittelforschung; 1998 Jun; 48(6):641-5. PubMed ID: 9689420
[TBL] [Abstract][Full Text] [Related]
8. A combined single and multiple dose pharmacokinetic study of oral isosorbide-5-mononitrate in healthy volunteers.
Storm G; Oosterhuis B; Bron J; Wittebrood AJ; De Jong AP; Jonkman JH
Biopharm Drug Dispos; 1991 Dec; 12(9):661-72. PubMed ID: 1790311
[TBL] [Abstract][Full Text] [Related]
9. Plasma profile and haemodynamic tolerance to isosorbide-5-mononitrate in controlled-release form.
Jähnchen E
Br J Clin Pharmacol; 1992; 34 Suppl 1(Suppl 1):15S-17S. PubMed ID: 1633073
[TBL] [Abstract][Full Text] [Related]
10. Twenty-four hour plasma profile of sustained-release isosorbide mononitrate in healthy volunteers and in patients with chronic stable angina. Two open label trials.
Baxter T; Eadie CJ
Br J Clin Pharmacol; 1997 Mar; 43(3):333-5. PubMed ID: 9088592
[TBL] [Abstract][Full Text] [Related]
11. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
Darwish M; Yang R; Tracewell W; Robertson P; Bond M
Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
Jenner P; Könen-Bergmann M; Schepers C; Haertter S
Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the bioequivalence and pharmacokinetics of two tablet formulations of isosorbide-5-mononitrate after single oral administration in healthy volunteers.
Niopas I; Daftsios AC; Nikolaidis N
Arzneimittelforschung; 2002; 52(3):182-6. PubMed ID: 11963645
[TBL] [Abstract][Full Text] [Related]
14. In vitro dissolution and in vivo bioequivalence evaluation of two brands of isosorbide 5-mononitrate sustained release tablets.
Kim YH; Choi KS; Kam SH; Lee KH; Park JS
Arzneimittelforschung; 2012 Dec; 62(12):576-82. PubMed ID: 23093481
[TBL] [Abstract][Full Text] [Related]
15. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects.
Darwish M; Bond M; Tracewell W; Robertson P; Yang R
Clin Drug Investig; 2015 Jan; 35(1):13-22. PubMed ID: 25391549
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects.
Vaidyanathan S; Bartlett M; Dieterich HA; Yeh CM; Antunes A; Howard D; Dole WP
Cardiovasc Ther; 2008; 26(4):238-46. PubMed ID: 19035874
[TBL] [Abstract][Full Text] [Related]
18. Development of monolithic osmotic pump tablet system for isosorbide-5-mononitrate delivery and evaluation of it in vitro and in vivo.
Duan X; Liu Q; Zhang Y; Bi K; Chen X; Wang Y; Luo G
Drug Dev Ind Pharm; 2009 Apr; 35(4):499-507. PubMed ID: 18979308
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of isosorbide mononitrate.
Abshagen UW
Am J Cardiol; 1992 Nov; 70(17):61G-66G. PubMed ID: 1449102
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris.
Chrysant SG; Glasser SP; Bittar N; Shahidi FE; Danisa K; Ibrahim R; Watts LE; Garutti RJ; Ferraresi R; Casareto R
Am J Cardiol; 1993 Dec; 72(17):1249-56. PubMed ID: 8256699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
